Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

SOURCE:

This study, led by Maria-Victoria Mateos, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, was presented at ASCO Plenary Series: February 2024 Session and published in the Journal of Clinical Oncology.

LIMITATIONS:

Open-label design was a limitation of this study. Follow-up for overall survival was ongoing.

DISCLOSURES:

This study was funded by GSK. Dr. Mateos reported receiving honoraria, consulting/personal fees outside this work.

A version of this article first appeared on Medscape.com.